Belzutifan for cancers linked to VHL or HIF-2α changes
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old (or at least 18 for a specific VHL group called Cohort B1)
- Have one of these diagnoses: advanced/metastatic PPGL, pancreatic neuroendocrine tumor (pNET), VHL disease–related tumors, wild-type GIST, or certain advanced solid tumors with HIF-2α-related gene changes
- For Cohort B1: have a confirmed VHL diagnosis from a germline (inherited) test or your doctor’s diagnosis
- Have a life expectancy of at least 3 months
- Be able to swallow and absorb the study medicine (you should not have issues that stop absorption)
- Not need extra oxygen long-term, and your resting oxygen level (fingertip reading) should not be below 92%
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests an oral drug called belzutifan in adolescents with specific types of solid tumors, such as pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumors, or tumors linked to von Hippel-Lindau disease. It aims to see if the drug can shrink or control these tumors.
This study tracks how well belzutifan (a new medication) works for patients with VHL-spectrum disease, a genetic condition that causes tumors. You'll be monitored over time to see how the drug affects your health and quality of life.
Hear when a new Pheochromocytoma/Paraganglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.